A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
A phase 2 trial of PM8002, Bevacizumab and Temozolomide in glioma & glioblastoma, run by BioNTech SE, now recruiting.
Overview
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma is a phase 2 interventional study registered as NCT07297212 by BioNTech SE, with 75 participants planned, started 2026-01-15 and due to reach its primary completion in 2028-01. Interventions recorded: Pumitamig, Bevacizumab and Temozolomide.
Setting
A Phase II, Multi-site, Open-label Trial Evaluating the Safety and Efficacy of Pumitamig and Bevacizumab as Monotherapy and Pumitamig in Combination With Temozolomide in Patients With Recurrent Glioblastoma
Phase
Phase 2
Sponsor
BioNTech SE
Registry
Enrolled
75
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Shares PM8002, BioNTech, Bristol Myers Squibb and the tag pipeline.
- TrialGlioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients
Shares Temozolomide, Bevacizumab, Glioma & glioblastoma and the tag pipeline.
- TrialA Study of PM8002 in Combination With Chemotherapy in Patients With SCLC
- TrialPM8002 in the Treatment of Patients With Advanced Solid Tumors
- TrialA Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- TrialA First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors
- TrialA Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC
- TrialA Study of PM8002 in Combination With Chemotherapy in Patients With NEN